Valuation: Annexon, Inc.

Market Cap 860M 747M 696M 640M 1.21B 81.82B 1.22B 8.21B 3.21B 40.9B 3.23B 3.16B 136B P/E 2026 *
-5.57x
P/E 2027 * -6.19x
Enterprise Value 766M 665M 620M 569M 1.08B 72.84B 1.09B 7.31B 2.86B 36.41B 2.88B 2.81B 121B EV / Sales 2026 *
-
EV / Sales 2027 * 14.1x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day+2.76%
1 week+8.65%
Current month+5.99%
1 month-9.40%
3 months-5.10%
6 months-10.60%
Current year+7.57%
1 week 4.76
Extreme 4.76
5.48
1 month 4.76
Extreme 4.76
6.58
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 65 01/12/2014
Director/Board Member 67 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
2/19/26 A Free

Chief Technology Officer

312,500 0.2159%
2/19/26 A Free

Chief Executive Officer

1,250,000 0.8637%
2/19/26 A Free

Executive/Senior Manager

312,500 0.2159%
Change 5-day change 1-year change 3-year change Capi.($)
+2.76%+8.65%+113.44%+59.76% 860M
+10.00%+13.39%+51.99%+83.45% 56.7B
+0.80%-5.70%+23.89%+62.65% 51.97B
-0.63%-1.10%-16.90%-14.13% 23.33B
+0.46%-5.01%-11.08%+349.80% 21.34B
+1.73%-1.57%+32.81%-25.80% 17.44B
+4.29%+1.67%+201.24%+344.48% 14.77B
+1.95%-0.50%+52.76%+177.41% 13.84B
+3.88%+3.96%+441.63%+181.77% 12.12B
+5.84%-5.11%+63.80%+162.88% 11.14B
Average +3.12%-0.33%+95.36%+138.23% 22.35B
Weighted average by Cap. +3.77%+0.45%+62.61%+117.60%

Financials

2026 *2027 *
Net sales - 40.38M 35.06M 32.69M 30.03M 56.8M 3.84B 57.42M 385M 151M 1.92B 152M 148M 6.36B
Net income -188M -164M -153M -140M -265M -17.92B -268M -1.8B -703M -8.96B -708M -692M -29.69B -191M -166M -155M -142M -268M -18.16B -271M -1.82B -712M -9.08B -717M -701M -30.07B
Net Debt -94.47M -82.03M -76.48M -70.26M -133M -8.99B -134M -902M -352M -4.49B -355M -347M -14.88B -292M -253M -236M -217M -411M -27.77B -415M -2.79B -1.09B -13.88B -1.1B -1.07B -45.99B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
04/08/26 $5.400 +2.86% 1,220,231
03/08/26 $5.250 +3.04% 2,691,798
31/07/26 $5.095 -3.32% 2,800,727
30/07/26 $5.270 +8.44% 2,612,790
29/07/26 $4.860 -2.21% 3,464,094
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.250USD
Average target price
13.25USD
Spread / Average Target
+152.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock